Intercept Pharma (ICPT) Posts Mixed Q2 Results: Updates on Ocaliva

Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($3.14), $0.55 better than the analyst estimate of ($3.69). Revenue for the quarter came in at $5.52 million versus the consensus estimate of $1.72 million.

Ocaliva Commercial Update

Following a 17 to 0 FDA Advisory Committee vote in favor of accelerated approval, Ocaliva was approved by the FDA on May 27 for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Intercept launched Ocaliva in June 2016 and in conjunction launched Interconnect®, a comprehensive, personalized program that connects patients with dedicated Care Coordinators who help them understand their disease and provides treatment support and, for eligible patients, financial assistance options.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• FS Bancorp (FSBW) Tops Q1 EPS by 8c
• VIST Financial Corp. (VIST) Misses Q1 EPS by 19c